Anavex Life Sciences Corp (AVXL)

[Hoskuld]

Good post. Still, it is important for dose optimization to focus on efficacy as well as safety. If only very stable schizophrenia patients were enrolled (is 6 weeks stability unusual or typical?) then the logic regarding lack of efficacy is logical. Still, if no efficacy, then are the biomarker stand-ins sufficient to identify optimal dosing? IDK. We don't really know more now that what we already expected as a bare minimum: 3-71 is safe.

OTOH, 3-71 is potentially a P3-ready program. Not as obviously as KarXT because its P2 results were stat sig and 3-71 PANSS must not be. Hopefully, Anavex will provide more info that points to a winning P3 trial design and explains why their plan will succeed.